These are peer-reviewed supplementary tables for the article ' Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain ' published in the Jo
Background Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed
Figure S1. Model schematic.Curves provided in this image are hypothetical to illustrate how health state occupancy is determined. OS: overall survival; PD: progressed disease; PF: progression f
Amid increasing awareness regarding opioid addiction, medical marijuana has emerged as a substitute to opioids for pain management. Concurrently, opioid manufacturers are putting significant research